Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 397-401

  Makino, Hisashi ^a   Harada Shiba, Mariko ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cardiovascular disease; Familial hypercholesterolemia; LDL apheresis; Pregnancy

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; AORTA VALVE STENOSIS; APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; HOMOZYGOSITY; HUMAN; LONG TERM CARE; PREGNANCY; PRIORITY JOURNAL; REVIEW; XANTHOMA;

CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; PLASMAPHERESIS; PREGNANCY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0041815984     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00073.x     Document Type: Review

References (31)

1. Goldstein JL, Brown MS. Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic Basis of Inherited Disease, 6 edn. New York: McGraw-Hill, 1989;1215-51.
2. Yamamoto A, Kamiya T, Yamamura T. Clinical features of familial hypercholesterolemia. Arteriosclerosis 1989;9:166-74.
3. Beppu S, Nimura Y, Sakakibara H et al. Supravalvular aortic stenosis and coronary ostial stenosis in familial hypercholesterolemia: two-dimensional echocardiographic assessment. Circulation 1983;67:878-84.
4. Illingworth R. How effective is drug therapy in heterozygous familial hypercholesterolemia. Am J Cardiol 1993;72:D54-8.
5. Bilheimer D. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. Artheriosclerosis 1989;9:1158-63.
6. Grossmann M, Raper SE, Kozarsky K et al. Successful ex vivo gene therapy directed to liver in patient with familial hypercholesterolemia. Nat Genet 1944;6:335-41.
7. Yamamoto A, Kojima S, Harada-Shiba M et al. Plasmapheresis for prevention and regression of coronary atherosclerosis. Ann NY Acad Sci 1995;748:429-40.
8. Yamamoto A, Kawaguchi A, Harada-Shiba M, Tsushima M, Kojima S. Apheresis technology for prevention and regression of atherosclerosis: an overview. Ther Apher 1997;1:233-41.
9. DeGenne JL, Toutaine R, Maunand B, Truffert J, Laudat P. Forme homozygous cutaneo-tendineuses de xanthomatose hypercholesterolemique dans une observation familiale exemplaire. Essai de plasmapherese a titre de traitment heroique. Bull Mem Soc Hop Paris 1967;118:1377-402 (in French).
10. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975;1:1005.
11. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Specific removal of low-density-lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-22.
12. Yokoyama S, Hayashi R, Kikkawa T et al. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis (LA-01); characterization and experimental use of hypercholesterolemia rabbits. Arteriosclerosis 1984;4:276-82.
13. Takada S, Tani N, Ohnishi M, Kau A, Narisada U. Automated continuous low density lipoprotein absorption system. In: Oda T, ed. Therapeutic Plasmapheresis VII. Cleveland: ISAO Press, 1988;454-9.
14. Armstrong VW, Windisch M, Wieland H et al. Selective continuous elimination of low-density lipoproteins with heparin at acidic pH. Trans Am Soc Artif Intern Organs 1983;29:323-7.
15. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17:640-52.
16. Yokoyama S, Yamamoto A, Hayashi R, Satani M. LDL apheresis: potential procedure for prevention and regression of atheromatous vascular lesion. Jpn Circ J 1987;51:1116-22.
17. Uauy R, Zweiner RJ, Phillips MJ, Petruska ML, Bilheimer DW. Treatment of children with homozygous familial hypercholesterolemia: Safety and efficacy of low-density lipoprotein apheresis. J Pediatr 1992;120:892-8.
18. Mol MJTM, Stalenhoef AFH. Homozygous familial hypercholesterolemia: metabolic studies and treatment with LDL apheresis. Neth J Med 1990;36:297-87.
19. Naito C, Yamamoto A, Saito Y et al. Long term effect of LDL apheresis in Japan. Biomat Art Cells Immob Biotech 1991;19:19-26.
20. Tatami R, Inoue N, Itoh H et al. Regression of coronary atherosclerosis by combined LDL apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
21. Koga N. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. Ther Apher 1997;1:260-70.
22. Koga N, Watanabe K, Kurashige Y, Sato T, Hiroki T. Long-term effects of LDL apheresis in familial hypercholesterolaemic patients. J Int Med 1999;246:35-43.
23. Barss V, Phillippe M, Greene MF. Pregnancy complicated by homozygous hypercholesterolemia. Obstet Gynecol 1985;65:756-7.
24. Beigel Y, Hod M, Fuchs J et al. Pregnancy in homozygous familial hyperecholesterolemic patient treated with long-term plasma exchange. Am J Obstet Gynecol 1990;162:79-81.
25. Kroon AA, Swinkels DW, van Dongen PWJ, Stalenhoef AFH. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism 1994;43:1164-70.
26. Hankins GDV, Wendel GD, Leveno KJ. Myocardial infarction during pregnancy: a review. Obstet Gynecol 1985;65:139-46.
27. Harada-Shiba M, Tajima S, Yokoyama S et al. Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arterioscl Thromb 1992;12:1071-8.
28. Marais AD, Naourova RP, Firth JC, Penny C, Newwirth CKY, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997;38:2071-8.
29. Bisgaier CL, Essenburg AD, Auerbach BJ et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res 1997;38:2502-15.
30. Burnett JR, Wilcox LJ, Telford DE et al. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in minature pigs. Arterioscl Thromb Vascul Biol 1997;17:2589-600.
31. Yamamoto A, Harada-Shiba M, Kawaguchi A et al. The effect of atrovastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL apheresis therapy. Atherosclerosis 2000;153:89-98.